Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2023-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim of this study will evaluate the Impact of Covid-19 vaccine on Safety and Efficacy of Hematological Patients Received Allogeneic Hematopoietic Stem Cell Transplantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Impact of Donor COVID-19 Infection Status on the Recipient in Allo-HSCT

NCT05675826

COVID-19 Hematopoietic Stem Cell Transplantation

UNKNOWN

Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients

NCT05185817

Hematopoietic Stem Cell Transplantation (HSCT) COVID-19 Vaccines Immune System Tolerance

UNKNOWN PHASE2

Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients

NCT04723706

Hematologic Disorders and Bone Marrow Failure, Hematopoietic Stem Cell Transplantation (HSCT) or Cellular Therapy (CART)

COMPLETED

Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT

NCT04738981

Graft Vs Host Disease

COMPLETED PHASE3

Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia

NCT06378060

Severe Aplastic Anemia

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Since the first detection of a Corona Virus Disease 2019 (COVID-19) infection in late 2019, the syndrome coronavirus-2 (SARS-CoV-2) has spread rapidly across the globe, threatening the health and safety of an increasing number of people. The development of the SARS-CoV-2 vaccine has been shown to be effective in reducing the chance of COVID-19 infection and the severity of the disease. To control the COVID-19 pandemic, an increasing number of studies are calling for people to receive the SARS-CoV-2 vaccine, and the Chinese government is also advocating universal vaccination. However, the investigators have found in our work that as vaccination has become more widespread, clinicians have become somewhat confused about whether they can choose someone who has been vaccinated against SARS-CoV-2 as a donor for a bone marrow transplant, and what is the optimal time for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in vaccined hematological patients. This study will evaluate the impact of Covid-19 vaccine on safety and efficacy of hematological patients received allo-HSCT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

donor with vaccine, patient without vaccine

Patients don' t receive COVID-19 vaccine before allo-HSCT but whose donors receive one dose or more doses COVID-19 vaccine(s) before stem cell collection.

COVID-19 vaccine(donor)

Intervention Type BIOLOGICAL

Donor received COVID-19 vaccine before stem cells collection.

donor without vaccine, patient with vaccine

Patients receive one dose or more doses COVID-19 vaccine(s) before allo-HSCT but whose donors don't receive COVID-19 vaccine before stem cell collection.

COVID-19 vaccine(donor)

Intervention Type BIOLOGICAL

Donor received COVID-19 vaccine before stem cells collection.

COVID-19 vaccine(patient)

Intervention Type BIOLOGICAL

Patient received COVID-19 vaccine before allo-HSCT.

donor with vaccine, patient with vaccine

Patients receive one dose or more doses COVID-19 vaccine(s) before allo-HSCT and whose donors also receive one dose or more doses COVID-19 vaccine(s) before stem cell collection.

COVID-19 vaccine(patient)

Intervention Type BIOLOGICAL

Patient received COVID-19 vaccine before allo-HSCT.

donor without vaccine, patient without vaccine

Patients don' t receive COVID-19 vaccine before allo-HSCT and whose donors also don't receive COVID-19 vaccine before stem cell collection.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COVID-19 vaccine(donor)

Donor received COVID-19 vaccine before stem cells collection.

Intervention Type BIOLOGICAL

COVID-19 vaccine(patient)

Patient received COVID-19 vaccine before allo-HSCT.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Allogeneic hematopoietic stem cell transplantation is expected to start in the short term.
2. Able and willing to provide written informed consent and comply with all requirements for study participation (including all study procedures).

Exclusion Criteria

1. Patients or donors with a history of previous infection with SARS-Cov-2.
2. Patients or donors are currently infected with SARS-Cov-2.
3. Patients have a history of other malignancies, disease progression, or is currently on systemic therapy.

Eligible Sex

ALL

Accepts Healthy Volunteers

No